When<unk> es are treated, the prognosis for the mother is very good in Western countries; maternal death is rare, but most fetuses die or are aborted. For instance, in the UK, between 2003 and 2005 there were 32,100<unk> es resulting in 10 maternal deaths (meaning that 1 in 3,210 women with an<unk>  died). In 2006–2008 the UK Confidential Enquiry into Maternal Deaths found that<unk>  is the cause of 6 maternal deaths (.26/100,000<unk> es). In the developing world, however, especially in Africa, the death rate is very high, and<unk> es are a major cause of death among women of childbearing age. In women having had an<unk> , the risk of another one in the next<unk>  is around 10%. Future fertility Fertility following<unk>  depends upon several factors, the most important of which is a prior history of infertility. The treatment choice does not play a major role; a randomized study in 2013 concluded that the rates of intrauterine<unk>  two years after treatment of<unk>  are approximately 64% with radical surgery, 67% with medication, and 70% with conservative surgery. In comparison, the cumulative<unk>  rate of women under 40 years of age in the general population over two years is over 90%. Methotrexate does not affect future fertility treatments. The number of oocytes that were retrieved before and after treatment with methotrexate does not change. In case of ovarian<unk> , the risk of subsequent<unk>  or infertility is low. There is no evidence that massage improves fertility after<unk> .
Ectopic pregnancy
Miscarriage
Ovarian torsion
Appendicitis
Tubo-ovarian abscess
Ovarian cyst
Ovarian pregnancy
Dysmenorrhea